MeSH term
Frequency | Condition_Probility | Animals | 14 | 0.0 |
Cholesterol, Dietary/*administration & dosage | 3 | 27.0 |
*Diet | 4 | 1.0 |
Dietary Fats/*administration & dosage | 5 | 6.0 |
Genotype | 12 | 0.0 |
Humans | 195 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Particle Size | 3 | 1.0 |
Quantitative Trait, Heritable | 2 | 3.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
Alcohol Drinking | 3 | 2.0 |
Apolipoproteins/genetics | 2 | 8.0 |
Dietary Fats/administration & dosage | 2 | 2.0 |
Female | 116 | 0.0 |
Fishes | 2 | 2.0 |
Male | 129 | 0.0 |
Adolescent | 30 | 0.0 |
Apolipoproteins/blood | 14 | 6.0 |
Apolipoproteins E/*genetics | 5 | 0.0 |
Child | 22 | 0.0 |
Cholesterol/blood | 31 | 2.0 |
English Abstract | 32 | 0.0 |
Gene Frequency | 11 | 0.0 |
Lipids/*blood | 36 | 6.0 |
Lipoproteins/blood | 9 | 2.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Triglycerides/blood | 36 | 2.0 |
Adult | 90 | 0.0 |
Body Composition | 3 | 1.0 |
Cross-Sectional Studies | 16 | 1.0 |
Korea/epidemiology | 2 | 3.0 |
Middle Aged | 92 | 0.0 |
Questionnaires | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 96 | 0.0 |
Viral Load | 2 | 0.0 |
Aged | 55 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Analysis of Variance | 8 | 0.0 |
*Dietary Supplements | 2 | 3.0 |
Probability | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Lipoproteins, LDL/*blood | 4 | 2.0 |
Regression Analysis | 10 | 0.0 |
Lipids/*metabolism | 6 | 2.0 |
Mice | 6 | 0.0 |
Apolipoproteins A/blood | 5 | 7.0 |
Apolipoproteins B/*blood | 8 | 5.0 |
Cohort Studies | 8 | 0.0 |
Comparative Study | 35 | 0.0 |
Lipids/blood | 13 | 2.0 |
Reference Values | 7 | 0.0 |
Child, Preschool | 5 | 0.0 |
Pilot Projects | 2 | 0.0 |
Prospective Studies | 8 | 0.0 |
Risk Factors | 33 | 0.0 |
Double-Blind Method | 9 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 26 | 4.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Treatment Outcome | 6 | 0.0 |
Alleles | 13 | 0.0 |
Alu Elements/*genetics | 2 | 6.0 |
*Polymorphism, Genetic | 14 | 0.0 |
Russia | 2 | 2.0 |
Age Distribution | 3 | 0.0 |
Dietary Fats/*pharmacology | 4 | 6.0 |
Energy Intake | 3 | 1.0 |
Lipoproteins, HDL Cholesterol/*blood | 10 | 4.0 |
Polymorphism, Genetic | 8 | 0.0 |
Population Surveillance | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Sex Distribution | 3 | 1.0 |
Apolipoprotein A-I/metabolism | 5 | 6.0 |
Cells, Cultured | 3 | 0.0 |
Cholesterol/*metabolism | 3 | 1.0 |
Base Sequence | 12 | 0.0 |
Case-Control Studies | 8 | 0.0 |
*Glycoproteins | 4 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Prevalence | 6 | 0.0 |
Taiwan/epidemiology | 3 | 2.0 |
Variation (Genetics) | 3 | 0.0 |
Apolipoproteins/*blood | 15 | 9.0 |
Lipoproteins/*blood | 23 | 3.0 |
Apolipoprotein A-I/*blood | 6 | 18.0 |
Body Mass Index | 12 | 1.0 |
Retrospective Studies | 5 | 0.0 |
Testosterone/*blood | 2 | 0.0 |
Apolipoprotein A-I/blood | 14 | 12.0 |
Apolipoproteins B/blood | 15 | 5.0 |
Greece | 2 | 2.0 |
Lipoprotein(a)/blood | 7 | 10.0 |
*Genetic Markers | 4 | 1.0 |
C-Reactive Protein/*metabolism | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/*blood | 3 | 3.0 |
Diagnosis, Differential | 5 | 0.0 |
Lipoproteins, HDL/blood | 4 | 1.0 |
Apolipoproteins/*genetics | 3 | 4.0 |
Diet | 3 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Postprandial Period | 2 | 2.0 |
*Alleles | 2 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 4 | 1.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
Lipoproteins, HDL Cholesterol/blood | 30 | 4.0 |
Phenotype | 8 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Blood Pressure | 5 | 0.0 |
Linear Models | 2 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
Sex Factors | 4 | 0.0 |
Skinfold Thickness | 2 | 2.0 |
Insulin Resistance | 2 | 1.0 |
Apolipoprotein A-I/*genetics | 8 | 27.0 |
DNA Primers | 2 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Lipoprotein(a)/*blood | 5 | 5.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Singapore | 2 | 4.0 |
*Variation (Genetics) | 4 | 0.0 |
Lipoproteins, LDL/blood | 4 | 1.0 |
Glucose Clamp Technique | 2 | 1.0 |
Insulin Resistance/*physiology | 2 | 2.0 |
Lipoproteins, LDL/*chemistry | 2 | 9.0 |
Blood Glucose/metabolism | 5 | 0.0 |
*Body Mass Index | 2 | 2.0 |
Time Factors | 12 | 0.0 |
Apolipoproteins A/blood/*genetics | 2 | 16.0 |
Pedigree | 5 | 0.0 |
Lipoproteins/*blood/chemistry | 2 | 16.0 |
Lipoproteins, VLDL/blood | 2 | 0.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Antilipemic Agents/*therapeutic use | 7 | 9.0 |
Coronary Disease/*blood | 2 | 3.0 |
Drug Therapy, Combination | 3 | 0.0 |
Simvastatin/*therapeutic use | 3 | 13.0 |
Chromosome Mapping | 3 | 0.0 |
Triglycerides/*blood | 5 | 1.0 |
Administration, Oral | 2 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Age Factors | 3 | 0.0 |
*Anthropometry | 2 | 6.0 |
Body Weight | 4 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Rats | 4 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Fibrinogen/*metabolism | 2 | 2.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Family Health | 4 | 0.0 |
Heterozygote | 2 | 0.0 |
Syndrome | 3 | 0.0 |
Insulin/blood | 4 | 0.0 |
Leptin/blood | 2 | 3.0 |
Cholesterol/*blood | 4 | 1.0 |
Fish Oils/*pharmacology | 2 | 20.0 |
Rats, Wistar | 2 | 0.0 |
*Blood Component Removal | 2 | 6.0 |
Predictive Value of Tests | 5 | 0.0 |
Apolipoproteins C/genetics | 2 | 5.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Fatty Acids/blood | 2 | 4.0 |
Oxidation-Reduction | 3 | 0.0 |
Phospholipids/blood | 5 | 3.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Apolipoprotein A-I/genetics | 3 | 15.0 |
Apolipoproteins A/analysis | 2 | 33.0 |
Apolipoproteins C/blood | 3 | 10.0 |
Chromatography, Gel | 2 | 0.0 |
Smoking | 4 | 1.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Triglycerides/metabolism | 2 | 1.0 |
Asia | 2 | 2.0 |
Coronary Angiography | 3 | 1.0 |
DNA/analysis | 4 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Blood Glucose/analysis | 4 | 0.0 |
Exercise | 2 | 1.0 |
Amino Acid Sequence | 3 | 0.0 |
*Micelles | 2 | 20.0 |
Glucose Tolerance Test | 2 | 0.0 |
Sex Characteristics | 7 | 1.0 |
Infant | 2 | 0.0 |
Nutritional Status | 2 | 1.0 |
Lipids/*blood/classification | 2 | 50.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Obesity | 2 | 3.0 |
Anthropometry | 2 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Biological Markers/blood | 5 | 0.0 |
Creatinine/blood | 4 | 1.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
Serum Albumin/metabolism | 2 | 1.0 |
Uremia/blood | 2 | 11.0 |
Models, Genetic | 2 | 0.0 |
Arteriosclerosis/blood | 2 | 8.0 |
Haplotypes/*genetics | 3 | 1.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Lipids/blood/*metabolism | 2 | 11.0 |
Apolipoproteins E/*blood | 2 | 3.0 |
Chi-Square Distribution | 2 | 0.0 |
Apolipoprotein A-I/blood/*genetics | 2 | 22.0 |
Haplotypes | 4 | 0.0 |
Patient Compliance | 2 | 1.0 |
Mutation | 3 | 0.0 |
Creatine Kinase/blood | 2 | 1.0 |
Smoking/blood | 3 | 7.0 |
Cell Line | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Apolipoproteins C/*genetics | 5 | 5.0 |
Pregnancy | 2 | 0.0 |
HIV Infections/*blood | 2 | 4.0 |
Serum Albumin/analysis | 2 | 1.0 |
Diabetes Mellitus, Type 2/*complications | 2 | 5.0 |
Protein Binding | 2 | 0.0 |
Apolipoproteins A/*genetics | 5 | 10.0 |
Linkage Disequilibrium | 5 | 0.0 |
*Multigene Family | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Risk | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/metabolism | 2 | 4.0 |
gamma-Glutamyltransferase/blood | 2 | 4.0 |
Apolipoprotein A-I/analysis | 3 | 15.0 |
Apolipoproteins B/analysis | 3 | 10.0 |
Cardiovascular Diseases/*blood/epidemiology | 2 | 25.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
Molecular Weight | 2 | 0.0 |
Albuminuria | 2 | 4.0 |
Fibrinogen/analysis | 2 | 1.0 |
Lipoproteins, VLDL Cholesterol/blood | 2 | 3.0 |
Kinetics | 2 | 0.0 |
Temperature | 2 | 0.0 |
Apolipoprotein A-I | 8 | 7.0 |
Apolipoproteins A/*chemistry | 2 | 50.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Dietary Proteins/*administration & dosage | 2 | 7.0 |
*Exercise Therapy | 2 | 7.0 |
Blotting, Southern | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Acute Disease | 2 | 0.0 |
Statistics | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Apolipoproteins A/*blood | 2 | 4.0 |
Obesity/*blood | 2 | 2.0 |